AurorA-TT

About The Fund

AurorA-TT is a venture capital and technology transfer intermediation firm that was established in 2017 and maintains its headquarters in Milan, Italy. They dedicate their services to fostering the growth of early-stage biotechnology and pharmaceutical companies with an Italian base. Their commitment lies in providing investment to pre-seed and seed projects, aiming to bridge the significant gap that frequently exists between fundamental research and the industrial development of drugs. AurorA-TT does so by instilling industrial discipline in the projects they select for investment. Their approach to sourcing promising projects involves cultivating strong connections with various entities in the life science ecosystem. This includes partnerships and interactions with universities, research facilities, technology transfer offices, biotech firms as well as patient foundations. By tapping into these resources, AurorA-TT is able to identify and engage with projects right at their early discovery phase, which can lead to significant contributions in therapeutic developments. Their investment portfolio strategically emphasizes areas like oncology, immunology, rare diseases, infectious diseases, cardiovascular diseases, and disorders of the central nervous system (CNS). Despite this focus, AurorA-TT is known for their versatility and openness to exploring other innovative and high-potential sectors in life sciences, such as HealthTech, Fitness, Nanotechnology, and Life Science more broadly. The essence of their investment thesis revolves around nurturing seed and early-stage ventures in these specified fields, ensuring the advancement of significant health and medical solutions from the foundational research stages to market-ready products and therapies that could transform patient lives.